[Malignant atrophic papulosis (Köhlmeier-Degos disease). Failure to respond to interferon alpha-2a, pentoxifylline and aspirin]

Hautarzt. 2002 Sep;53(9):618-21. doi: 10.1007/s00105-002-0347-7.
[Article in German]

Abstract

A 45 year old female patient presented with the cutaneous manifestations of malignant atrophic papulosis (Köhlmeier-Degos disease) for two years. The typical papules with central porcelain-white atrophy correspond histologically to wedge-shaped necrosis of the connective tissue due to thrombotic occlusion of small vessels in the corium. The pathogenesis of malignant atrophic papulosis and effective treatment modalities are unknown. A slow virus infection has been suggested by some authors. Therefore, we attempted an immune therapy with interferon alpha-2a over a period of 11 months, but failed to cause a significant effect on the appearance and progression of the skin lesions. Furthermore, we could not confirm the effectiveness of a recently reported treatment modality with pentoxifylline and aspirin administered to our patient over a period of 5 months.

Publication types

  • Case Reports

MeSH terms

  • Aspirin / administration & dosage*
  • Atrophy
  • Connective Tissue / blood supply
  • Connective Tissue / pathology*
  • Diagnosis, Differential
  • Disease Progression
  • Drug Therapy, Combination
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Middle Aged
  • Pentoxifylline / administration & dosage*
  • Recombinant Proteins
  • Skin / blood supply
  • Skin / pathology
  • Skin Diseases, Papulosquamous / drug therapy*
  • Skin Diseases, Papulosquamous / immunology
  • Skin Diseases, Papulosquamous / pathology
  • Skin Diseases, Vascular / drug therapy*
  • Skin Diseases, Vascular / immunology
  • Skin Diseases, Vascular / pathology
  • Slow Virus Diseases / drug therapy*
  • Slow Virus Diseases / immunology
  • Slow Virus Diseases / pathology
  • Thrombosis / drug therapy*
  • Thrombosis / immunology
  • Thrombosis / pathology
  • Treatment Failure

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Aspirin
  • Pentoxifylline